NEW YORK— Americans are quietly eating less, and it’s starting to show up on the books of the country’s biggest food companies. The cause isn’t a recession or the latest diet fad. It’s a class of weight-loss drugs—Ozempic, Wegovy, Mounjaro, and Zepbound—that switch off hunger. About one in eight U.S. adults now takes one, and this spring the first cheap, easy-to-swallow pill versions reached pharmacy shelves.

Wall Street is already doing the math on the fallout. J.P. Morgan projects these drugs could erase $30 billion to $55 billion in annual U.S. food and beverage sales by the early 2030s, as users take in about 21% fewer calories and spend roughly 31% less at the grocery store.

Here’s why that number is so big.

The drugs were built to treat diabetes, but they also quiet the brain’s hunger signals, so people feel full sooner and snack less. In April, Eli Lilly won approval for Foundayo, the first weight-loss pill that can be taken without food or water restrictions, and it’s now reaching retail pharmacies. Novo Nordisk has a pill out, too. Cheaper, needle-free options are expected to pull millions more people onto the drugs—J.P. Morgan sees the U.S. user base climbing toward 25 million to 30 million people by 2030, up from about 10 million in 2025.

When that many people eat less, the grocery cart changes.

A Cornell University study tracked roughly 150,000 households and found that within six months of starting the drugs, families cut grocery spending by an average of 5.3%. Higher-income households cut more than 8%. Spending at fast-food restaurants and coffee shops fell about 8%, too. The cuts landed right where food companies make some of their best margins: sweets and salty snacks dropped around 10%. Yogurt, meanwhile, went up. People are swapping chips and candy for protein and fiber.

This is the part that worries Big Food, and the biggest brands are scrambling.

Conagra, which makes Healthy Choice meals, slapped a “GLP-1 friendly” label on more than two dozen of its frozen dinners. Nestlé launched a line called Vital Pursuit aimed directly at people taking the drugs. The shift is now significant enough that nearly three dozen non-healthcare companies discussed GLP-1 medications on earnings calls earlier this year, up from just 14 companies a year earlier.

Restaurants are rewriting menus, too. Olive Garden, owned by Darden Restaurants, added a lighter-portions section. The Cheesecake Factory rolled out smaller bowls and smaller meals. Shake Shack launched a “Good Fit Menu” featuring lettuce-wrapped burgers with up to 52 grams of protein. Even McDonald’s says it is testing high-protein, GLP-1-friendly items as it prepares for more customers with smaller appetites.

The math behind those changes is difficult for some chains. Bank of America found that snacking accounts for roughly 12% of sales at limited-service restaurant chains such as McDonald’s and Taco Bell—and snacking is exactly what these drugs are designed to reduce.

Not everyone is losing. The same medications reducing food consumption are generating enormous growth elsewhere. J.P. Morgan expects the global market for these drugs to reach $200 billion by 2030. Pfizer paid $10 billion last year to acquire a drugmaker developing its own version after outbidding seven competing buyers. And Washington is leaning in: a new Medicare and Medicaid pilot program would cap costs for some patients at $50 per month, potentially expanding usage further.

In the short run, the hit to food companies remains modest—a fraction of overall sales. The industry still has time to adjust, and some companies are already finding growth opportunities in high-protein snacks, nutrition-focused products, and healthier prepared meals.

But the long-run signal is becoming difficult to ignore. For the first time, a medicine—not a tax, not a recession, and not a public-health campaign—is changing how much the country eats. The companies that spent a century getting Americans to eat more now have to figure out how to make money when millions of their best customers simply want less.

JBizNews Desk — New York

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.